在欧盟,欧盟委员会于2020年2月授予JNJ-4528孤儿药资格、2019年4月授予优先药物资格(PRIME)。 原文出处:Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
and TECVAYLI, its refractory multiple myeloma medication, whose sales grew by 43.5% to $135 million. According to management, these advances were supported by the successful expansion of manufacturing capabilities and excellent market demand. Products like ERLEADA (treatment...
参考文献 https://www.prnewswire.com/news-releases/janssen-reports-new-data-for-bcma-car-t-cilta-cel-showing-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-multiple-myeloma-301302779.html
We continue to drive strong sales growth across our multiple myeloma portfolio. DARZALEX growth was 21.3%, primarily driven by share gains of 4.6 points across all lines of therapy and 9.4 points in the frontline setting, as well as market growth. CARVYKTI achieved sales of $186 million with ...
Other standout performers include CARVYKTI, its myeloma medication, whose sales advanced by 59.9% to $186 million, and TECVAYLI, its refractory multiple myeloma medication, whose sales grew by 43.5% to $135 million. According to management, these advances were supported by the successful expansion...
其中就不得不提血液系统的第二大常见恶性肿瘤——多发性骨髓瘤(Multiple Myeloma,MM),约占血液系统恶性肿瘤的10%,侵袭性强,几乎无法治愈。虽然全球已有数十款上市的治疗药物,但以靶向药物和单抗类药物居多,即便如此,仍有不少患者无法取得理想的生存获益。尤其是占20%~30%的多发性骨髓瘤高危患者,临床未满足的需求...
teclistamab的生产和开发遵循了杨森生物科技公司与Genmab签订的使用DuoBody®技术平台的许可协议。 原文出处:Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma 简要说明书...
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia. 2009; 23 :1894–903.Deleu, S.; Lemaire, M.; Arts, J.; Menu, E.; van Valckenborgh, E.; King, P.; vande ...
And, Geoff, to your point, in multiple myeloma and new product launches, we are also very encouraged by the launch of TECVAYLI and also the recent approval of TALVEY. The progression of these medicines is exceeding our internal expectations. And we already have about 2,000 healthcare profes...
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to...